Oculus Innovative Sciences Announces Proposed Public Offering of Common Stock
and Intention to Repay Certain Indebtedness
PETALUMA, Calif., March 6, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) today announced that it intends to offer for sale
its common stock in an underwritten public offering. Oculus intends to use the
net proceeds from this offering for the repayment of debt and for general
corporate purposes. In connection with the repayment of debt, the company
intends to retire a portion of the common stock previously issued to its
The offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering. Aegis Capital Corp. is acting as the
sole book-running manager for the offering.
The offering is being made pursuant to a shelf registration statement that
Oculus previously filed with the Securities and Exchange Commission (the
"SEC") and which is effective. A preliminary prospectus supplement and
accompanying base prospectus relating to the offering will be filed with the
SEC and will be available on the SEC's website located at www.sec.gov.
Electronic copies of the preliminary prospectus supplement, when available,
and accompanying base prospectus may be obtained by contacting Aegis Capital
Corp., Prospectus Department, 810 Seventh Avenue, 18^th Floor, New York, NY,
10019, telephone: 212-813-1010 or email: email@example.com.
This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.
About Oculus Innovative Sciences
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial healthcare
company that designs, produces and markets innovative, safe and effective
drugs, devices and nutritional products. Oculus is pioneering innovative
solutions in multiple markets for the dermatology, surgical, wound care and
animal healthcare markets, and has commercialized products in the United
States, Europe, India, China, Mexico and select Middle East countries. The
company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.
Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "intends," "proposed" and"retire,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.
Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.
CONTACT: Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Press spacebar to pause and continue. Press esc to stop.